Remibrutinib for Hidradenitis Suppurativa

This trial focuses on testing remibrutinib, a new treatment for individuals with moderate to severe hidradenitis suppurativa (HS), a skin condition that causes painful lumps under the skin. The goal is to assess the long-term safety and effectiveness of this medication. Participants in this trial have already completed an earlier study phase with remibrutinib. Those who finished the previous study without stopping treatment early might be suitable candidates for this trial. As a Phase 3 trial, it represents the final step before FDA approval, providing an opportunity to contribute to bringing a new treatment to market.

The trial does not specify if you must stop taking your current medications, but it excludes those with ongoing or planned use of certain treatments. It's best to discuss your specific medications with the study team.

Previous studies have shown that patients tolerate remibrutinib well. Research indicates no major concerns about liver safety with this treatment, and no cases have met the criteria for serious liver injury, suggesting a favorable safety profile. Additionally, a high percentage of patients with moderate to severe hidradenitis suppurativa (HS) who took remibrutinib experienced significant improvement in their condition. Overall, the data suggest that remibrutinib is safe to use, with only minimal side effects reported.¹²³⁴⁵

Most treatments for hidradenitis suppurativa, like antibiotics and biologics such as adalimumab, focus on reducing inflammation and infection. However, Remibrutinib is unique because it targets Bruton's tyrosine kinase (BTK), a protein involved in the inflammatory process, potentially offering a new way to calm the immune system. Researchers are excited about Remibrutinib because it could provide relief for patients who don't respond well to current options by directly modulating the immune response. Additionally, having multiple doses (Dose A and Dose B) allows researchers to optimize effectiveness and minimize side effects, enhancing treatment personalization.

Research has shown that remibrutinib may help treat hidradenitis suppurativa (HS). In one study, 72.7% of patients taking remibrutinib experienced significant improvement, including fewer painful lumps and abscesses, which are common in HS. In this trial, participants will receive either Remibrutinib Dose A or Dose B at random. The treatment proved effective at different doses, with the lower dose group achieving better results. Overall, remibrutinib has demonstrated strong potential in reducing symptoms for people with moderate to severe HS.¹²³⁴⁵